-
Department of Defense Awards $5.7M Contract to PharmAthene
Tuesday, August 16, 2011 - 9:02am | 52PharmAthene, Inc. (NYSE: PIP) announced today that the Company has been awarded a $5.7 million contract under a Department of Defense Broad Agency Announcement for studies directed at the development of an advanced expression system for the bioproduction of its nerve agent medical countermeasure...
-
Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
Tuesday, August 16, 2011 - 9:02am | 135Marshall Edwards, Inc. (Nasdaq: MSHL) announced today that its Investigational New Drug application for ME-143 (formerly NV-143), the Company's lead NADH oxidase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA). The Company plans to initiate a Phase I clinical trial of...
-
Icagen Reiterates Its Recommendation That Stockholders Accept Pfizer's Offer of $6 Per Share
Tuesday, August 16, 2011 - 8:32am | 343Icagen, Inc. (Nasdaq: ICGN) announced today that it has mailed the following letter to stockholders reiterating its recommendation that Icagen stockholders accept the $6 per share tender offer by Pfizer Inc. (NYSE: PFE): August 16, 2011 Dear Icagen Stockholder: You should have recently received...
-
J.P. Morgan Adding Gilead Sciences To Focus List
Tuesday, August 16, 2011 - 8:17am | 130J.P. Morgan Chase & Co. is out with a research report on Gilead Sciences (NASDAQ: GILD) and is adding it to the Focus List. It has an Overweight rating and a $50 price target on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "We are adding Gilead to the J.P. Morgan Analyst...
-
Nabi Biopharmaceuticals Announces Receipt of $5 Million Milestone Payment
Tuesday, August 16, 2011 - 8:03am | 66Nabi Biopharmaceuticals (Nasdaq: NABI) has received a $5 million payment from Fresenius USA Manufacturing, Inc. that was triggered by the first commercial sale of Phoslyra, a milestone under the agreement governing the Company's 2006 sale of PhosLo and related assets to Fresenius. These assets...
-
Curis Announces Dosing of First Patient in Phase I CUDC-101 Head and Neck Cancer Combination Trial
Tuesday, August 16, 2011 - 8:01am | 213Curis, Inc. (NASDAQ: CRIS) today announced that the first patient has been treated in a Phase I combination trial of CUDC-101. The Phase I trial is the Company's first CUDC-101 combination study and is designed to test CUDC-101 when administered concurrently with radiation and cisplatin in human...
-
UPDATE: Piper Jaffray Upgrades Alnylam Pharmaceuticals to Overweight
Tuesday, August 16, 2011 - 7:55am | 97Piper Jaffray is out with its report today on Alnylam Pharmaceuticals (NASDAQ: ALNY), upgrading ALNY to Overweight from Neutral. In its report, Piper Jaffray writes, "We look for upside as Alnylam reports Phase I proof-of-concept data on orphan drug ALN-TTR01 and high cholesterol drug ALN-PCS both...
-
Benzinga's Top Upgrades
Tuesday, August 16, 2011 - 7:37am | 133Benchmark Company upgraded Hess Corporation (NYSE: HES) from “sell” to “buy.” Hess' shares closed at $60.21 yesterday. Hess' PEG ratio is 0.64. Analysts at Credit Suisse upgraded Allergan Inc (NYSE: AGN) from “neutral” to “outperform.” AGN's shares closed at $74.75 yesterday. Allergan's trailing-...
-
JP Morgan Adds Gilead Sciences To Analyst Focus list
Tuesday, August 16, 2011 - 6:15am | 30JP Morgan has added Overweight-rated Gilead Sciences (NASDAQ: GILD) to its JP Morgan Analyst Focus List. Price target is currently set at $50.
-
Piper Jaffray Upgrades Alnylam Pharmaceuticals To Overweight, Raises PT To $12
Tuesday, August 16, 2011 - 6:12am | 28Piper Jaffray has upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Neutral to Overweight and has raised the price target from $10 to $12.
-
Earnings Scheduled For August 16
Tuesday, August 16, 2011 - 4:19am | 481TJX Companies Inc (The) (NYSE: TJX) is expected to report its Q2 EPS at $0.89 on revenue of $5.44 billion. Home Depot Inc (The) (NYSE: HD) is projected to report its Q2 EPS at $0.83 on revenue of $19.96 billion. Saks Incorporated (NYSE: SKS) is estimated to post a Q2 loss at $0.09 per share on...
-
Mad Money Lightning Round: Cramer Likes Starbucks, BJ's Restaurants
Tuesday, August 16, 2011 - 4:16am | 244On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Caterpillar (NYSE: CAT) has “been a difficult stock to own but I think Caterpillar is dirt cheap. I refuse to throw in the towel and continue to own it." For Public Storage (NYSE: PSA), he said, "I like the real estate...
-
NPS Pharmaceuticals Announces Amended Amgen Agreement and Plan to Retire Sensipar-Backed Series B Notes
Monday, August 15, 2011 - 4:31pm | 134NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today announced that the company intends to retire the 15.5% Secured Class B Notes when they become redeemable at par value on September 30, 2011. The company also announced that it has entered into an agreement with Amgen that becomes effective after the...
-
Myriad Announces New $200 Million Share Repurchase Program
Monday, August 15, 2011 - 4:15pm | 155Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that its Board of Directors has authorized a new $200 million stock repurchase program. "This announcement is the result of our commitment to a balanced capital deployment approach," said James Evans, Chief Financial Officer of Myriad Genetics,...
-
AVI BioPharma Initiates Dosing in Phase 2 Study of Eteplirsen in Duchenne Muscular Dystrophy Patients
Monday, August 15, 2011 - 4:05pm | 145AVI BioPharma, Inc. (NASDAQ: AVII) today announced that it has initiated dosing in a Phase 2 study of eteplirsen, the Company's lead exon-skipping therapeutic candidate for the treatment of Duchenne muscular dystrophy. The placebo-controlled study of twelve patients, which will be conducted at...